Abstract:Upregulation of epidermal growth factor receptor (EGFR) and subsequent increases in extracellular-regulated kinase (ERK) and Akt signaling are implicated in prostate cancer progression. Impaired endocytic downregulation of EGFR also contributes to oncogenic phenotypes such as metastasis. Thus, understanding the roles of divergent signaling pathways in the regulation of EGFR trafficking and EGFR-driven invasive migration may enable the development of more effective therapies. In this study, we use the human prostate cancer cell lines, DU145 and PC3, to investigate the effects of both the ERK and Akt pathways on epidermal growth factor (EGF)-mediated EGFR signaling, trafficking and cell motility. We show that DU145 and PC3 cells overexpress EGFR and migrate in a ligand (EGF)-dependent manner. Next, we show that pharmacological inhibition of ERK (but not Akt) signaling enhances EGF-induced EGFR activation, ubiquitination and downregulation, and may lead to enhanced receptor turnover. These findings negatively correlate with ERK-mediated threonine phosphorylation of EGFR, implicating it as a possible mechanism. Further, we uncover that EGF promotes disassembly of cell–cell junctions, downregulation of E-cadherin and upregulation of the transcriptional repressor, Snail, typical characteristics of epithelial–mesenchymal transition (EMT). These effects are dependent on activation of Akt, as inhibition of Akt signaling abolishes EGF/EGFR-driven cell migration and EMT. Knockdown of endogenous Snail also prevents EGFR-mediated downregulation of E-cadherin, EMT and cell migration. Surprisingly, inhibition of the ERK pathway augments EGFR-dependent motility, occurring concomitantly with elevation of EGF-induced Akt activity. Collectively, our results suggest that EGF-triggered ERK activation has profound feedback on EGFR signaling and trafficking by EGFR threonine phosphorylation, and Akt has a pivotal role in EGFR-mediated cell migration by activating EMT. More important, our results also suggest that therapeutic targeting of ERK signaling may have undesirable outcomes (for example, augmenting EGFR-driven motility).

ERK1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility

Ribosomal Protein S6 Kinase (RSK)-2 As a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells

Extracellular Signal-Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration By Maintaining Slug Expression

Data from Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression

ERK2 Is a Promoter of Cancer Cell Growth and Migration in Colon Adenocarcinoma

Novel roles for ERK5 and cofilin as critical mediators linking ERα-driven transcription, actin reorganization, and invasiveness in breast cancer

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

A Positive Feedback Between Activated Extracellularly Regulated Kinase and Cyclooxygenase/Lipoxygenase Maintains Proliferation and Migration of Breast Cancer Cells

The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer

ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation

Myosin Light-Chain Kinase Contributes to the Proliferation and Migration of Breast Cancer Cells Through Cross-Talk with Activated ERK1/2

MAP4K4 regulates biomechanical forces at adherens junctions and focal adhesions to promote collective cell migration

Altered MAP Kinase (ERK1,2) Regulation in Primary Cultures of Mammary Tumor Cells: Elevated Basal Activity and Sustained Response to EGF.

ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity

Estradiol-Induced Epithelial to Mesenchymal Transition and Migration Are Inhibited by Blocking c-Src Kinase in Breast Cancer Cell Lines

The G protein-coupled receptor TBXA2R activates ERMs to control cell motility and invasion of triple-negative breast cancer cells

Excitable Rho dynamics control cell shape and motility by sequentially activating ERM proteins and actomyosin contractility

Interdependency and differential expression of ERK1 and ERK2 in breast and melanoma cell lines

Mechanical Control of Cell Migration by the Metastasis Suppressor Tetraspanin CD82/KAI1

The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent